Stocksigma LogoStocksigma Logo

GSK Pharma Delivers Strong Q2 FY27 Results Driven by Innovation and Established Portfolio

GSK India reported record Q2 FY27 revenue of INR 1,180 crore, up 21% YoY (underlying growth 12-13%), driven by healthy 5-7% GenMed volume growth

GSK Pharma Delivers Strong Q2 FY27 Results Driven by Innovation and Established Portfolio

GlaxoSmithKline Pharmaceuticals Ltd 路 Transcript 路 08 Nov 2026, 7:12 pm

GSK Pharma Delivers Strong Q2 FY27 Results Driven by Innovation and Established Portfolio GSK India reported record Q2 FY27 revenue of INR 1,180 crore, up 21% YoY (underlying growth 12-13%), driven by healthy 5-7% GenMed volume growth. EBITDA rose 20% YoY to INR 400 crore with stable 34% margins, while PAT grew 33% YoY (underlying 21%), aided by an INR 42 crore one-off tax refund interest. The balance sheet remained zero-debt with INR 2,200 crore cash and a 98% cash conversion ratio. The innovation portfolio reached 7% of revenues, supported by Shingrix doubling sales. Blenrep is scheduled to launch in Q3.

Original exchange filing (PDF)

More announcements from GlaxoSmithKline Pharmaceuticals Ltd

All GlaxoSmithKline Pharmaceuticals Ltd announcements